Vancouver, July 26th, 2024 — Lophos Holdings Inc. (“Lophos” or the “Company”) (CSE:MESC), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”), announces that it has received a Notice of Sale Under Mortgage, affecting its property located at 100 Circuit Rider Drive, Napanee, Ontario. The notice states that default has been […]
Vancouver, July 24th, 2024 — Lophos Holdings Inc. (“Lophos” or the “Company”) (CSE:MESC), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) today announced that John Karagiannidis will be stepping down from the Board of Directors due to personal reasons, effective July 23, 2024. The Chairman of the Board of Directors […]
June 20, 2024 5:00 PM EDT | Source: Lophos Holdings Inc. Vancouver, British Columbia–(Newsfile Corp. – June 20, 2024) – Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused […]
Napanee, Ontario–(Newsfile Corp. – May 15, 2024) – Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”) proudly announces the traditional blessing of its Napanee site, paying homage to the indigenous heritage of its founders and sanctifying the grounds for the cultivation of Lophophora williamsii (peyote) moving forward. The ceremony, led by esteemed elders, holds […]
NAPANEE, Ontario, May 06, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos”, or the “Company”) (CSE:MESC) is pleased to announce that its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. (“Lophos Pharma”) – a biosciences company specializing in the cultivation, research, and sale of Lophophora williamsii (peyote), announced today that it has entered into a letter of intent […]
NAPANEE, Ontario, May 02, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos”, or the “Company”) (CSE:MESC) is pleased to announce the official commencement of its first research protocol under its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. The protocol, centered on the cultivation of Lophophora williamsii (Peyote), marks a significant milestone in Lophos’ dedication to advancing sustainable […]
VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”) proudly announces a milestone accomplishment from its subsidiary, Lophos Pharmaceuticals Corp. Specializing in the cultivation, research, and commercialization of peyote, the company has completed the propagation of an additional three thousand (3,000) seeds, marking a significant expansion […]
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos” or the “Company”) (CSE:MESC) is delighted to announce the successful receipt of building occupancy for its subsidiary, Lophos Pharmaceuticals Corp., in Napanee, Ontario. This milestone achievement follows the dedicated efforts of Carmichael Engineering Ltd., the esteemed HVAC engineering and construction firm based […]
VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD”), a publicly traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, and Lophos Holdings Inc. (“Lophos”), have entered into a Securities Purchase Agreement (“Agreement”) on April 12, 2024. Under the terms of […]
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company“) is pleased to announce all matters presented for approval at the annual general meeting of the shareholders of the Company held earlier today March 28, 2024 (the “Meeting“) have been approved. A total of 26,839,013 common shares […]
We specialize in plant-based psychedelic research and cultivation, and we support the traditional use of psychedelic medicines.
We endeavor to provide safe access to plant-based therapeutics and to discover and develop new pharmachological treatments for disorders that may find relief in psychedelic based therapies.
